HK Stock Market Move | CONCORD HC GP(02453) opened more than 6%, its subsidiary Guangzhou Taihe Cancer Hospital has been approved to enter the list of designated medical institutions of "Hong Kong and Macao Medical Devices Pass"

CONCORD HC GP (02453) opened more than 6%, as of the time of writing, it has risen by 6.12% to HKD 2.08, with a turnover of HKD 100,700. On the news front, CONCORD HC GP announced that its subsidiary, Guangzhou Taihe Cancer Hospital, has been approved by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration to enter the list of designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area "Hong Kong-Macao Medical Device Access" on December 8, 2025. "Hong Kong-Macao Medical Device Access" is a key measure of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation and Development Plan". Designated medical institutions in the Greater Bay Area that are included in the list can import and use Guangdong-Hong Kong-Macao special medical drug policies, allowing designated medical institutions to use clinically urgently needed drugs and advanced medical devices already on the market in Hong Kong and Macao with approval. This qualification allows the company to become a professional oncology medical institution with the qualification to use innovative medical devices in Hong Kong and Macao. The company can be the first to introduce and use urgently needed oncology medical devices in the field, including new original drugs that have been listed in China's Hong Kong and Macao but have not yet been approved domestically, further expanding its business scope, forming a differentiated competitive advantage in the market, providing urgently needed drugs to more cancer patients, and strengthening the company's competitive advantage in the field of oncology medical treatment.